PsilOCD: A Pharmacological-Challenge Feasibility Study

Launched by IMPERIAL COLLEGE LONDON · Feb 5, 2024

Keywords

ClinConnect Summary

The PsilOCD study is a clinical trial looking at how psilocybin, a natural substance found in certain mushrooms, might help people with Obsessive-Compulsive Disorder (OCD). The researchers want to see if psilocybin can improve thinking flexibility and the brain's ability to adapt. They are currently recruiting participants aged 20 to 65 who have been diagnosed with OCD for at least a year and can attend study visits, some of which may be done online.

To be part of the trial, participants should be comfortable using a computer and have internet access. There are certain health conditions that would exclude someone from participating, like a history of substance use disorders or certain mental health issues. If eligible, participants can expect to take part in sessions where they will receive psilocybin and be monitored for its effects. This study aims to help improve understanding of OCD and potentially lead to new treatment options in the future.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Aged 20 to 65 years;
• • Any gender;
• • A primary diagnosis of OCD (based on the Mini-International Neuropsychiatric Interview (M.I.N.I.));
• • Has met diagnostic criteria for OCD for at least 12 months;
• • Willing to comply with protocol and associated lifestyle restrictions;
• • Adequate understanding of the English language to give informed consent and participate in the study;
• • Participant can attend visits as an outpatient;
• • Comfortable using a computer, access to internet from home, and willing to participate in some of the study visits via video-link.
• Key Exclusion Criteria:
• • Current or past history of dependent (according to ICD10 criteria) substance use (not including nicotine and/or caffeine), Tourette's syndrome, autism spectrum disorder, epilepsy, organic mental disorder, or a personality disorder apart from obsessive-compulsive personality disorder;
• • Current or past history of psychosis or mania in themselves or a first-degree relative;
• • Unstable physical health;
• • Significantly abnormal clinical test result;
• • Heavy smoker, or unable to attend the dosing days (including the subsequent recovery part) without a smoking break;
• • Unwillingness to allow their GP or mental health practitioners to be informed of their participation (or, to allow study team access to Summary Care Record).